April 2nd 2020
By The Center for Biosimilars
Following close on the heels of its US approval for Ruxience (rituximab), Pfizer has gained the European Commission nod and aims to launch in coming months.
By Christina Corridon, MPH, MBA
The coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.
April 1st 2020
By Skylar Jeremias
Self-insured companies could have saved $407 million to $1.4 billion in 2018 had they switched completely from reference biologics infliximab and filgrastim to biosimilars.
March 31st 2020
Russian company Biocad gains distribution rights for its rituximab and trastuzumab biosimilars in Bosnia and Herzegovina.
By Tony Hagen
Canadian provinces encounter opposition in their move to implement forced switching of patients from reference products to biosimilars.
March 28th 2020
China is getting the hang of producing biosimilars, and harvest time is on the near horizon, according to a new report.
March 24th 2020
The FDA has approved a multidose vial of Samsung Bioepis’ trastuzumab biosimilar Ontruzant, which was first approved as a 150-mg single-dose vial in January 2019 and has yet to reach the US market in either form.
As coronavirus disease 2019 (COVID-19) causes medical systems to bog down from a host of related issues, a UT Health expert said clinical trials likely will be powered down and hospitals will put consideration of newly available agents on hold.
February 12th 2020
By Deana Ferreri, PhD
By 2023, patents on nearly 20 oncology biologics will expire, which could lead to more biosimilars in cancer care and therefore reduced costs, according to a review article.
February 10th 2020
Biosimilars are starting to gain some traction in the marketplace, according to a speaker reviewing the 2020 pipeline at the Specialty Therapies and Biosimilars Congress.
